Quest PharmaTech Celebrates Successful AGM
Quest PharmaTech Inc. (TSX-V: QPT) proudly announced the results from its recent annual general meeting, an event that sets the stage for the company's strategies moving forward.
Re-elected Board of Directors
During the meeting, shareholders took part in a crucial vote, leading to the re-election of four distinguished members of the Board of Directors:
Distinguished Board Members
1. J. Mark Lievonen, C.M., FCPA, FCA, LLD
2. Jeffrey Shon, J.D.
3. Madi R. Madiyalakan, Ph.D.
4. Bradley J. Glass, J.D.
The re-elected board members bring a wealth of experience and expertise, promising to guide the company's future endeavors. Dr. Madi R. Madiyalakan, the CEO, expressed a positive outlook following the results, emphasizing the board's integral role in steering Quest's business strategy.
Shareholder Engagement
With approximately 50,288,000 shares voted, representing about 29.7% of eligible shares, shareholder participation showcased the community's strong commitment to the company's vision. The reappointment of Kingston Ross Pasnak, LLP as auditors was another significant outcome of the meeting.
Stock Options Granted
On a corporate level, the Board approved the granting of 1,900,000 stock options to Directors and Officers. This decision, with an exercise price set at $0.05 per share, aligns with the company’s long-term incentive strategy. The options are set to expire 10 years from the grant date, pending TSX Venture Exchange approval.
About Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canadian-based biopharmaceutical company that focuses on enhancing the quality of life through innovative therapeutics. Specifically, the company is advancing its proprietary product, MAb-AR9.6, which targets MUC16. This groundbreaking agent is in the late preclinical stage of development and was licensed from the University of Nebraska Medical Centre.
Strategic Collaborations
The company also holds a 42.5% stake in OncoQuest Inc., which has made significant strides in immunotherapy technology. Additionally, Quest’s 23% interest in OncoVent, a joint venture in China, underscores its commitment to developing antibody-based therapies for cancer treatment in the Greater China territory. The scope of Quest's efforts aligns with its mission to address critical healthcare needs.
Looking Ahead
With a strong leadership team and innovative product pipeline, Quest PharmaTech stands poised for future growth and advancements in cancer therapy. The strategic decisions made during the AGM reflect the company’s dedication to transparency and its focus on shareholder value.
For more detailed information, please reach out to Dr. Madi R. Madiyalakan, CEO of Quest PharmaTech Inc. You can contact him via telephone at (780) 448-1400 or via email, ensuring you're part of the journey as Quest continues to innovate in biopharmaceuticals.
Frequently Asked Questions
What were the key outcomes of the Quest PharmaTech AGM?
The AGM resulted in the re-election of four board members, the reappointment of auditors, and the granting of 1,900,000 stock options.
Who were the re-elected members of the Board of Directors?
The re-elected board members are J. Mark Lievonen, Jeffrey Shon, Madi R. Madiyalakan, and Bradley J. Glass.
What is the significance of the stock options granted?
The stock options, granted at $0.05 per share, serve as a long-term incentive for Directors and Officers, reinforcing their commitment to the company’s success.
What are Quest PharmaTech's primary areas of focus?
Quest focuses on developing innovative biopharmaceutical products, with a notable emphasis on cancer therapeutics through its proprietary product, MAb-AR9.6.
How can I contact Quest PharmaTech for more information?
You can reach out to Dr. Madi R. Madiyalakan via telephone at (780) 448-1400 or through email for inquiries.
